Cybin Inc. announced a strategic partnership with Osmind, a leading service provider in advancing psychiatry through technology and real-world evidence. This collaboration aims to accelerate commercial preparation for Cybin's clinical-stage programs, including CYB003 and CYB004.
Cybin will leverage Osmind's extensive network of over 800 psychiatry clinics in the U.S., along with its point-of-care software and real-world data. This partnership focuses on aligning and preparing the operational infrastructure necessary for interventional treatments, covering areas such as pharmacy, fulfillment, patient access, and reimbursement.
The partnership is a critical step in laying the groundwork for the commercialization of CYB003, currently in Phase 3 development for Major Depressive Disorder, and CYB004, in a Phase 2 study for Generalized Anxiety Disorder. This initiative supports Cybin's mission to scale cutting-edge mental health treatments to patients in need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.